ReviewCellular and molecular life sciences : CMLS2018
Epigenetic mechanisms of tumor resistance to immunotherapy.
Review in Cellular and molecular life sciences : CMLS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Harnessing the immune system in the treatment of cutaneous T cell lymphomas.Frontiers in oncology · 2022Pooled it
- Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis : an international journal on programmed cell death · 2026Review
- Article
- Targeting EZH2 in autoimmune diseases: unraveling epigenetic regulation and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Beyond the genome: epigenetic regulation of immune responses and T cells in brain tumors.Frontiers in immunology · 2025Review
- Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.Aging · 2022Review
- Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers.World journal of gastrointestinal oncology · 2022Review
- Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.Cancer immunology, immunotherapy : CII · 2022Article
- Emerging Therapies in Penile Cancer.Frontiers in oncology · 2022Review
- HDAC Inhibition to Prime Immune Checkpoint Inhibitors.Cancers · 2021Review
- Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial.ESMO open · 2021Review
- Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer.Molecules and cells · 2021Review
- LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance.Science advances · 2021Article
- The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.Cancers · 2021Review
- An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer.Nature communications · 2020Article
- The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".Theranostics · 2020Review
- The roles of DNA, RNA and histone methylation in ageing and cancer.Nature reviews. Molecular cell biology · 2019Review
- Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program.Journal of oncology · 2019Article
- Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy.American journal of clinical and experimental urology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The recent impact of cancer immunotherapies has firmly established the ability and importance of the immune system to fight malignancies. However, the intimate interaction between the highly dynamic tumor and immune cells leads to a selection process driven by genetic and epigenetic processes. As the molecular pathways of cancer resistance mechanisms to immunotherapy become increasingly known, novel therapeutic targets are being tested in combination with immune-stimulating approaches. We here review recent insights into the molecular mechanisms of tumor resistance with particular emphasis on epigenetic processes and place these in the context of previous models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.